title: Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
abstract: Cytarabine is one of the most effective antineoplastic agents among those used for the treatment of acute myeloid leukemia. However, some patients develop resistance and/or severe side effects to the drug, which may interfere with the efficacy of the treatment. The polymorphisms of some Ara-C metabolizing enzymes seem to affect outcome and toxicity in AML patients receiving cytarabine. We conducted this study in a cohort of Mexican pediatric patients with AML to investigate whether the polymorphisms of the deoxycytidine kinase and cytidine deaminase enzymes are implicated in clinical response and toxicity. Bone marrow and/or peripheral blood samples obtained at diagnosis from 27 previously untreated pediatric patients with de novo AML were processed for genotyping and in vitro chemosensitivity assay, and we analyzed the impact of genotypes and in vitro sensitivity on disease outcome and toxicity. In the multivariate Cox regression analysis, we found that age at diagnosis, wild-type genotype of the CDA A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death.
authors.affiliation: Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico.
authors.forename: Aurora
authors.initials: A
authors.lastname: Medina-Sanson
authors.affiliation: Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico.
authors.forename: Arturo
authors.initials: A
authors.lastname: Ramírez-Pacheco
authors.affiliation: Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico.
authors.forename: Silvia Selene
authors.initials: SS
authors.lastname: Moreno-Guerrero
authors.affiliation: Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico.
authors.forename: Elisa María
authors.initials: EM
authors.lastname: Dorantes-Acosta
authors.affiliation: Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico.
authors.forename: Metzeri
authors.initials: M
authors.lastname: Sánchez-Preza
authors.affiliation: Hospital Infantil de México Federico Gómez, Research Division, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Reyes-López
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003564:Cytidine Deaminase / Q000235:genetics*; D003643:Death; D003842:Deoxycytidine Kinase / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D003842:Deoxycytidine Kinase; D003564:Cytidine Deaminase